International Regulators Focus On Omicron XBB For Monovalent COVID-19 Vaccine
Executive Summary
A workshop led by the European Medicines Agency and the US Food and Drug Administration sought to reach alignment on adapting COVID-19 vaccines to emerging virus variants.
You may also be interested in...
SK Bioscience Pulls EU Filing For COVID Jab As Regulators Shift Focus To XBB Vaccines
The European Medicines Agency’s CHMP was set to adopt opinions on SK Bioscience’s COVID-19 vaccine and Mycovia/Gedeon’s Vivjoa for vulvovaginal candidiasis during its September meeting, but both marketing authorization filings were voluntarily withdrawn.
EMA Agrees Monovalent XBB Vaccines Best For Coming COVID-19 Campaigns
The European Medicines Agency says it is talking with international partners and pharmaceutical companies about the epidemiological situation with SARS-CoV-2 and how authorized COVID-19 vaccines can best be adapted to emerging variants.
Novavax Readying Multiple COVID-19 Vaccine Candidates To Ensure Fall Availability
CBER’s Marks said US FDA is working with Novavax on manufacturing to allow its protein-based vaccine to be ready for a fall roll-out. After some concerns about international coordination, multiple regulators seem to be settling on a monovalent approach for fall vaccinations.